Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$58.57T
24h Vol:
$4.78B
Dominance:
MSFT:5.14%
Stocklytics Platform
BETA
Instrument logo  AMAM

Ambrx Biopharma Inc.

AMAM
55 / 100
High Growth
$27.96arrow_drop_up0.07%$0.02

Income Statement (AMAM)

itemSep 2023Jun 2023Mar 2023Dec 2022Sep 2022
EBIT-$25.48M-$20.59M-$16.03M-$8.66M-$8.66M
EBITDA-$25.10M-$20.23M-$15.96M-$8.79M-$8.79M
gross Profit$53.00K$1.12M$24.00K$2.24M$2.24M
NET Income-$22.98M-$17.82M-$15.30M-$13.25M-$13.25M
total Revenue$53.00K$1.12M$24.00K$2.24M$2.24M

Balance Sheet (AMAM)

itemSep 2023Jun 2023Mar 2023Dec 2022Sep 2022
cash Equivalents-----
net Debt-$214.73M-$217.24M-$138.08M-$43.63M-
stockholders Equity$242.40M$250.38M$182.59M$117.85M-
total Assets$271.50M$279.94M$210.61M$146.97M-
total Debt$10.52M$11.01M$11.50M$11.97M-
total Liabilities$29.09M$29.56M$28.02M$29.12M-

Cash Flow (AMAM)

itemSep 2023Jun 2023Mar 2023Dec 2022Sep 2022
financing Cash Flow$9.71M$82.65M$77.22M-$506.00K$1.46M
free Cash Flow-$19.17M-$13.93M-$12.96M-$12.75M-$15.88M
investing Cash Flow-$9.18M$9.18M$8.74M$8.74M
operating Cash Flow-$18.87M-$13.15M-$12.96M-$12.70M-$15.77M

Ambrx Biopharma Inc. (AMAM) Financials

Ambrx Biopharma Inc. (AMAM) is a leading biopharmaceutical company that focuses on the development and commercialization of innovative protein therapeutics. The company's financials provide insights into its performance and financial health. The income statement presents the company's revenue and expenses over a specific period. It shows the gross profit, which is the revenue minus the cost of goods sold. The net income from stockholders indicates the company's profitability after accounting for all expenses and taxes. The total revenue reflects the overall income generated by the company. These financial indicators help investors assess the company's financial performance.

The balance sheet presents the company's assets, liabilities, and stockholders' equity at a specific time. It includes cash equivalents, which are highly liquid assets that can be easily converted into cash. Net debt represents the company's total debt minus its cash and cash equivalents. Stockholders' equity is the residual interest in the assets of the company after deducting liabilities. Total assets represent the company's resources that will provide future economic benefits. Meanwhile, total debt and liabilities include the company's obligations and financial responsibilities.

Cash flow refers to the movement of cash in and out of the company. Operating cash flow represents the amount of cash generated from the company's core operations. It shows the company's ability to generate cash from its primary business activities. Investing cash flow involves the cash used for acquiring and disposing of long-term assets and investments. Financing cash flow represents the cash flow from activities such as issuing stocks or paying dividends. Free cash flow is the cash remaining after deducting capital expenditures from operating cash flow. It indicates the company's ability to generate cash for other purposes.

Ambrx Biopharma Inc. (AMAM) strives to maintain a strong financial position and generate sustainable revenue. Its financials provide valuable insights into the company's performance, profitability, and ability to generate cash. These financial indicators help investors assess the company's financial health and make informed investment decisions. With a focus on innovation and commercialization, Ambrx Biopharma Inc. (AMAM) aims to contribute to the development of effective protein therapeutics that improve patients' lives.

add Ambrx Biopharma Inc. to watchlist

Keep an eye on Ambrx Biopharma Inc.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.